Abstract
The enzyme poly(ADP)-ribose polymerase-1 (PARP-1) plays an important role in the repair of DNA damage via a mechanism called base excision repair (BER). Initially, inhibition of PARP-1 showed to be a promising anti-tumor strategy in preclinical models using BRCA1 and BRCA2 deficient tumor cell lines. More recently, several small molecules targeting PARP-1 entered the clinic and demonstrated compelling anti-tumor activity in patients with BRCA deficient breast and ovarian cancers, and in patients with triple-negative breast cancer. In this review we aim to summarize the most recent advances in the development of PARP inhibitors, with a focus on the clinical data.
Keywords: Synthetic lethality, repair mechanism, PARP, BRCA deficient, olaparib
Current Clinical Pharmacology
Title: Inducing Synthetic Lethality using PARP Inhibitors
Volume: 5 Issue: 3
Author(s): David S. Boss, Jos H. Beijnen and Jan H.M. Schellens
Affiliation:
Keywords: Synthetic lethality, repair mechanism, PARP, BRCA deficient, olaparib
Abstract: The enzyme poly(ADP)-ribose polymerase-1 (PARP-1) plays an important role in the repair of DNA damage via a mechanism called base excision repair (BER). Initially, inhibition of PARP-1 showed to be a promising anti-tumor strategy in preclinical models using BRCA1 and BRCA2 deficient tumor cell lines. More recently, several small molecules targeting PARP-1 entered the clinic and demonstrated compelling anti-tumor activity in patients with BRCA deficient breast and ovarian cancers, and in patients with triple-negative breast cancer. In this review we aim to summarize the most recent advances in the development of PARP inhibitors, with a focus on the clinical data.
Export Options
About this article
Cite this article as:
S. Boss David, H. Beijnen Jos and H.M. Schellens Jan, Inducing Synthetic Lethality using PARP Inhibitors, Current Clinical Pharmacology 2010; 5 (3) . https://dx.doi.org/10.2174/157488410791498798
DOI https://dx.doi.org/10.2174/157488410791498798 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors
Current Alzheimer Research Flow Chemistry to Control the Synthesis of Nano and Microparticles for Biomedical Applications
Current Topics in Medicinal Chemistry MUC1 Story: Great Expectations, Disappointments and the Renaissance
Current Medicinal Chemistry Interleukin-10: An Anti-Inflammatory and Immunosuppressive Cytokine in the Normal and Pathological Immune Response
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents G Protein-Coupled Receptors in Regulation of Body Weight
CNS & Neurological Disorders - Drug Targets Dimer and Tetramer of Gallic Acid: Facile Synthesis, Antioxidant and Antiproliferative Activities
Letters in Drug Design & Discovery Development and Evaluation of Bioresponsive Tablets of a Selective COX-2 Inhibitor for Colonic Delivery
Drug Delivery Letters Pharmacogenetics of Phase I and Phase II Drug Metabolism
Current Pharmaceutical Design Up-regulation of microRNA-16 in Glioblastoma Inhibits the Function of Endothelial Cells and Tumor Angiogenesis by Targeting Bmi-1
Anti-Cancer Agents in Medicinal Chemistry Bioinformatics Approaches for Anti-cancer Drug Discovery
Current Drug Targets Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design Smell and Taste Disorders Resulting from Cancer and Chemotherapy
Current Pharmaceutical Design A Wrapper Based Binary Shuffled Frog Algorithm for Efficient Classification of Mammograms
Current Signal Transduction Therapy Diverse Roles of GADD45α in Stress Signaling
Current Protein & Peptide Science Long-circulating Targeted Nanoparticles for Cancer Therapy
Current Nanoscience Hybrid Imidazole-Pyridine Derivatives: An Approach to Novel Anticancer DNA Intercalators
Current Medicinal Chemistry Targeting Angiogenesis for Treatment of NSCLC Brain Metastases
Current Cancer Drug Targets FAK and p53 Protein Interactions
Anti-Cancer Agents in Medicinal Chemistry Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances
Central Nervous System Agents in Medicinal Chemistry Integrating the Universe of Effector and Regulatory Immune Cell Subsets: An Emerging Role of Protein-Glycan Interactions
Current Immunology Reviews (Discontinued)